Outcomes and Risk Factors of Patients With COVID-19 and Cancer (ONCORONA): Findings from The Philippine CORONA Study

Adrian I. Espiritu1,2,3†‡, Ramon B. Larrazabal Jr.4†‡, Marie Charmaine C. Sy1†, Emilio Q. Villanueva III5, Veeda Michelle M. Anlacan1† and Roland Dominic G. Jamora1,6†‡

1 Department of Neurosciences, College of Medicine and Philippine General Hospital, University of the Philippines Manila, Manila, Philippines, 2 Department of Clinical Epidemiology, College of Medicine, University of the Philippines Manila, Manila, Philippines, 3 Division of Neurology, Department of Medicine, St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada, 4 Division of Medical Oncology, Department of Medicine, College of Medicine and Philippine General Hospital, University of the Philippines Manila, Manila, Philippines, 5 Department of Pathology, College of Medicine and Philippine General Hospital, University of the Philippines Manila, Manila, Philippines, 6 Institute for Neurosciences, St. Luke’s Medical Center, Taguig, Philippines

Background: A study conducted in China on patients with coronavirus disease 2019 (COVID-19) showed that cancer conferred a five times increased risk for needing intensive care admission and mortality; No data has yet been collected and published from the Philippines. Thus, the investigators conducted this substudy to determine the association of having a history of cancer with clinical outcomes among patients included in the Philippine CORONA Study.

Methodology: Multi-center, retrospective cohort design

Results: A total of 244 patients had a history of cancer, out of 10,881 COVID-19 hospital admissions. After adjusting for different confounding variables of interest, having cancer was significantly associated with a 75% increased odds of having severe/critical COVID-19 at nadir (CI 95% 1.32, 2.33; p < 0.001). After adjusting for different confounding variables of interest, having cancer was significantly associated with the following time-to-event outcomes: 72% increase in hazard of in-hospital mortality (CI 95% 1.37, 2.16; p < 0.001), 65% increase in hazard of respiratory failure (CI 95% 1.31, 2.08; p < 0.001), and 57% increase in hazard of being admitted to ICU (CI 95% 1.24, 1.97; p < 0.001).

Conclusion: A history of cancer conferred poorer clinical outcomes on adult, hospitalized COVID-19 patients.

Keywords: cancer, mortality, respiratory failure, intensive care unit admission, outcomes, COVID-19
INTRODUCTION

On the 11th of March 2020, the World Health Organization declared that the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was a global pandemic (1). Since then, it has affected more than 420 million people, causing 5.86 million deaths, as of February 19, 2022 worldwide (2). At the same time in the Philippines, this pandemic has affected an estimated 3.65 million people with more than 55 thousand deaths (3).

Studies have been conducted worldwide that evaluated the demographic profiles, clinical characteristics and clinical outcomes among COVID-19 patients. There are other specific subgroups, such as those with cancer, that are susceptible to the disease and are associated with poorer clinical outcomes such as requiring oxygen support, needing intensive care, and increased mortality (4). A study conducted in Italy supported this when they showed that cancer conferred a near-doubled death rate among patients with cancer than those without who were infected with COVID 19 (5). Furthermore, the published data from the COVID-19 in patients with thoracic malignancies study and clinical impact of COVID-19 patients with cancer study, both being registries from different countries, showed that age, smoking, male sex, functional status, and the presence of active cancer were associated with higher mortality. Specifically, the COVID-19 study done by the Gustave Roussy Hospital identified that those older than 70 years old, with a smoking history, advanced cancer (metastatic), those undergoing cytotoxic chemotherapy, and those having an Eastern Cooperative Oncology Group performance status of more than or equal to 2 are risk factors that increased the risk of death (6).

The studies mentioned were conducted in Europe, South America, United States of America, Japan, and China; and no data was collected and published from the Philippines, a developing country with a different healthcare system (7). Thus, the investigators in collaboration with the Philippine CORONA Study Group conducted a substudy on the cohort of COVID-19 patients with a history of cancer; looking at their clinical outcomes (i.e., mortality, respiratory failure, duration of ventilator dependence, intensive care unit (ICU) admission, length of ICU and hospital stay compared to those with no history of cancer (8).

MATERIALS AND METHODS

Study Design

This was a retrospective substudy of patients with cancer enrolled in the Philippine CORONA study, which was a nationwide, multicentre, comparative, retrospective, cohort study of hospitalized patients with COVID-19 from February 2020 to December 2020. The study protocol was registered in ClinicalTrials.gov (NCT04386083) and published previously (8).

Study Setting

This substudy was based on the data gathered from 37 major hospitals/study sites from various regions in the Philippines. The specific sites are listed in the published study protocol (8).

Patient Selection

We included a total enumeration of all patients that fulfilled the inclusion criteria, as follows: adults older than or of 19 years of age; confirmed cases via COVID-19 real-time reverse transcription polymerase chain reaction (RT-PCR) of patients’ nasopharyngeal swab samples which were performed by testing centers accredited by the Department of Health (Philippines); clinical symptoms/signs ascribed to COVID-19 infection; patients with the appropriate disposition by the end of the data collection period (e.g., discharged, transferred to another hospital, or died). Individuals who were transferred to another hospital were excluded to prevent duplication of data. Adult COVID-19 patients who had new-onset neurological symptom/s (NNS) were grouped under the exposed cohort while those without NNS (non-NNS) were classified under the unexposed cohort. The information on the patient selection is detailed in the published study protocol (8).

Data Collection Procedure and Management

All investigators, sub-investigators, and hired data collectors obtained pertinent information for this study. An electronic data collection form was formulated using Epi Info™ Software (Version 7.2.2.16). The form was pilot-tested and a formal orientation and workshop was conducted to ensure accurate data collection as explained in the published protocol (8). Moreover, the data collection forms used did not contain any information that could identify the patients.

The following pertinent data were obtained: demographic data; other clinical profile data/comorbidities; neurological history; date of illness onset; respiratory and constitutional symptoms associated with COVID-19; COVID-19 disease severity at nadir; data if neurological manifestation/s were present at onset prior to respiratory symptoms and the specific neurological manifestation/s present at onset; neurological symptoms; date of neurological symptom onset; new-onset neurological disorders or complications; date of new neurological disorder or complication onset; imaging done; cerebrospinal fluid analysis; electrophysiological studies; treatment given; antibiotics given; neurological interventions given; date of mortality and cause/s of mortality; date of respiratory failure onset; date of mechanical ventilator cessation and cause/s of respiratory failure; date of first day of ICU admission, date of discharge from ICU and indication/s for ICU admission; other neurological outcomes at discharge; date of hospital discharge; and final disposition.

Statistical Analysis

Baseline characteristics and clinical outcomes of the patients were summarized by descriptive statistics. Numerical variables were described as mean and standard deviation, if the data were normally distributed as assessed by the Shapiro-Wilk test for normality, and as median and interquartile range, if otherwise. Categorical variables were described as frequency and proportion. These different baseline characteristics and clinical outcomes were compared between the two groups: with cancer, and without.
cancer. A significant difference in the mean/median/mean-rank of the different numerical variables between the two groups was determined by Student's t test for the variables with normally distributed data, while Mann-Whitney U test was done for non-normally distributed variables. Comparison of the proportions of the different categorical variables between the two groups was determined by chi-squared test or Fisher exact test.

The associations between having cancer and the different individual dichotomous outcome variables of interest were determined by multivariable binary logistic regression. Survival analysis was also done for time-to-event data of mortality, respiratory failure, and admission to ICU. The time-to-event were right-censored on time-to-discharge as the exit from the time-at-risk among those who have not experienced the event, i.e., mortality, respiratory failure, or admission to ICU, during the hospital stay. The associations between having cancer and the different time-to-event outcome variables of interest were determined by multivariable Cox proportional hazards regression. The logistic and Cox proportional hazards regression models were adjusted for the following pre-determined confounders: age group, sex, smoking status, hypertension, chronic cardiac disease, chronic respiratory disease, chronic kidney disease, and chronic neurologic disease. A cutoff of \( p < 0.05 \) identifies having cancer as a significant predictor of the different outcomes of interest. Kaplan-Meier curves were constructed to visualize the survival curves of those with cancer versus without cancer, adjusted for the different confounding variables of interest, and also for the different time-to-event outcome variables.

RESULTS

A total of 10,999 patients were hospitalized who tested positive for COVID 19 (by reverse transcription polymerase chain reaction) from February to December 2020 were included in the study. Initially, there were 118 patients who did not meet the age criteria, and were excluded in the final analysis in the published paper (9). Out of the 10,881 patients included in the final analysis, 244 of them had a history of cancer (see Figure 1).

Demographic and Clinical Profile

The participants’ age were divided into 2 categories: those aged 60 years and above and those aged 18-59 years. The cancer group had equal participants for both age groups [122 (50%) vs 122 (50%)], while majority of the group without cancer were belonged to the less than 60 years old age group [6925 (65.1%) vs 3,712 (34.9%), \( p < 0.001 \)]. There was a considerable number of women in the study and significantly more reported having no history of cancer [4950 (46.5%), \( p < 0.001 \)].

The most common non-neurologic co-morbidity reported was hypertension in both groups with and without cancer. There was a significant difference between groups, with those with a history of cancer reporting to have more hypertension [113 (46.3%) vs 3534 (33.2%), \( p < 0.001 \)]. The most common neurologic co-morbidity reported was a history of stroke which was significantly different between both groups [14 (5.7%) vs 307 (2.9%), \( p = 0.009 \)], higher in those with a history of cancer than those without.

The group of patients with cancer (or a history of cancer) was noted to have a significantly higher incidence of respiratory symptoms: cough [128 (52.5%) vs 4,283 (40.3%), \( p < 0.001 \)], dyspnea [98 (40.2%) vs 2605 (24.5%), \( p < 0.001 \)], and increased sputum production [28 (11.5%) vs 609 (5.7%), \( p < 0.001 \)]. It also showed that the cancer group was given more glucocorticoids [93 (38.1%) vs 2751 (25.9%), \( p < 0.001 \)], antiviral medications [60 (24.6%) vs 1842 (17.3%)], and antibiotics [221 (90.6%) vs 8793 (82.7%), \( p < 0.001 \)] as treatment for COVID 19, compared to those patients without a history of cancer. The cancer group

---

**FIGURE 1** | Flow of patients.
experienced more symptoms and needed more medications (see Table 1).

**Comparison of Outcomes of the Patients According to Whether They Have Cancer or Not**

Our study showed that there was significantly higher proportion of patients with cancer with the following outcomes of interest than those patients without cancer: severe/critical COVID-19 at nadir [125 (52.1%) vs 3936 (37.5%), \( p < 0.001 \)], in-hospital mortality [80 (32.8%) vs 1622 (15.3%), \( p < 0.001 \)], respiratory failure [76 (31.1%) vs 1532 (14.4%), \( p < 0.001 \)], intensive care unit (ICU) admission [78 (31.9%) vs 1662 (15.6%), \( p < 0.001 \)], hospital stay > 14 days [113 (46.3%) vs 4191 (39.4%), \( p = 0.026 \)], and neurologic presentation or complication [80 (32.8%) vs 2211 (20.8%), \( p < 0.001 \)] (see Table 2).

Additionally, there were significantly lower proportion of patients with cancer with the following outcomes of interest than those patients without cancer: IMV dependence > 5 days [234 (95.9%) vs 10,429 (98%), \( p < 0.032 \)] and full/partial neurologic recovery among patients with neurologic presentation at admission or neurologic complication during hospital stay [34 (72.3%) vs 1605 (86.3%), \( p < 0.001 \)].

**The Relationship of Clinical Outcomes of Interest Among Patients With and Without Cancer**

After adjusting for the different confounding variables of interest, having cancer was significantly associated with the following outcomes: those with cancer have 75% increased odds of having severe/critical COVID-19 at nadir [OR 1.75, 95% CI 1.32, 2.33], a 54% increased odds of having neurologic presentations/complications [OR 1.54, 95% CI 1.17, 2.03], and a 54% decreased odds of having full/partial neurological improvement if they have neurologic presentations/complications [OR 0.46, 95% CI 0.22, 0.93] (see Table 3).

After adjusting for the different confounding variables of interest, having cancer was significantly associated with the following time-to-event outcomes (see Table 4): 72% increase in hazard of in-hospital mortality [HR 1.72, 95% CI 1.37, 2.16], 63% increase in hazard of respiratory failure [HR 1.65, 95% CI 1.31, 2.08], and a 57% increase in hazard of being admitted to ICU [HR 1.57, 95% CI 1.24, 1.97]. The following outcomes are depicted in the Kaplan-Meier curves (see Figure 2).

**DISCUSSION**

Previous literature have shown that patients with cancer are as susceptible to being infected with the SARS-CoV-2 virus as those without (10, 11). This study emphasized that the cohort of COVID-19 patients with cancer had a higher risk for in-hospital mortality, respiratory failure, and needing intensive care. This was consistent with early studies reported in China (4–7). There was a 72% increase in in-hospital mortality was in stark contrast to the other studies that analyzed a similar cohort of patients done in New York City (12, 13). The investigators attribute this high mortality in our study to a difference in healthcare systems. In the Philippines the universal health care law is partially and poorly implemented (14) and majority of the Filipinos belong to the lower socioeconomic status (15). Since 1992, the Philippine Government has devolved the management and delivery of health services from the national Department of Health to locally elected provincial, city, and municipal governments. This was highlighted in a review of studies on the health care cost and financing of patients with malignancies (especially for those with central nervous system malignancies). The cost of care (especially in cancer care) in the country is not covered by most insurance companies and is scarcely subsidized by the state, which means that cancer care is an out-of-pocket cost for most if not all Filipinos (14, 15).

Our cohort also analyzed multiple centers nationwide, with varying levels of healthcare services, and not just a single-center study (9). There was also the consideration of poorer socioeconomic factors (residence in rural areas and low level of income) which are associated with increased mortality (16). The other outcomes of interest in this study were consistent with other studies such as respiratory failure and needing intensive care which, along with increased mortality, all portend to poor clinical outcomes shown in patients with cancer (6, 7).

In response to the surge of cases in the country, the Philippine General Hospital (PGH) was designated by the Philippine Department of Health as a COVID-19 referral center. The Department of Health also designated other institutions in different regions as COVID-19 referral centers. This meant that since March 31, 2020 non-emergency clinics, elective procedures and surgeries and non-COVID-19 admissions were intermittently being suspended or limited depending on the threat of the COVID surge. Realizing the possible detrimental effects of the cessation of oncologic care, the Cancer Institute adapted strategies that allowed the continuation of cancer care and maintained the safety and well-being of both the patients and the health professionals. Patients seen at the clinic were limited and appointments given were based on a prioritization scheme. The Philippine government has relegated the duty of vaccinating individuals to the local governments. As of this writing, 62.2 million people (56.8%) have been fully vaccinated (2).

The pandemic has a profound impact on cancer care in all aspects. Specifically, the screening, diagnosis, and treatment in both medical and surgical oncology. With the participants recruited many months into the pandemic, those patients with cancer might have had their treatment delayed due to the burden the pandemic imposed on the healthcare system (i.e. prioritizing patients with COVID-19) as well as the government response (i.e. logistics problem due to the numerous and repeated lockdowns imposed) (16). With these roadblocks to cancer care, an international collaborative group recommended a prioritization scheme that can maximize health benefits, taking into consideration the patient, their disease, and prognosis (17).

In our study, we were able to show a significant difference of neurologic manifestations between patients with and without...
|                         | With cancer (n = 244) | Without cancer (n = 10,637) | p-value |
|-------------------------|-----------------------|-----------------------------|---------|
| **Socio-demographic data** |                       |                             |         |
| Age group               |                       |                             | <0.001  |
| < 60 y, n (%)           | 122 (50.0)            | 6925 (65.1)                 |         |
| ≥ 60 y, n (%)           | 122 (50.0)            | 3712 (34.9)                 |         |
| Female, n (%)           | 149 (61.1)            | 4950 (46.5)                 | <0.001  |
| Ever-smoker (past/current), n (%) | 31 (12.7)             | 995 (9.4)                   | <0.001  |
| **Non-neurologic comorbidities, n (%)** |                       |                             |         |
| Hypertension            | 113 (46.3)            | 3534 (33.2)                 | <0.001  |
| Diabetes mellitus       | 64 (26.2)             | 2127 (20.0)                 | 0.016   |
| Chronic cardiac diseasea| 20 (8.2)              | 492 (4.6)                   | 0.009   |
| Chronic respiratory diseaseb| 12 (4.9)             | 604 (5.7)                   | 0.611   |
| Chronic kidney disease  | 24 (9.8)              | 587 (5.5)                   | 0.004   |
| Chronic liver disease   | 1 (0.4)               | 59 (0.6)                    | 1.000   |
| HIV/AIDS                | 1 (0.4)               | 36 (0.3)                    | 0.569   |
| **Past neurologic history, n (%)** |                       |                             |         |
| Stroke/cerebrovascular  | 14 (5.7)              | 307 (2.9)                   | 0.009   |
| Epilepsy                | 1 (0.4)               | 26 (0.2)                    | 0.458   |
| Neurodegenerativec      | 3 (1.2)               | 41 (0.4)                    | 0.075   |
| Headache syndrome       | -                     | 5 (0.0)                     | 1.000   |
| Demyelinating disorder  | -                     | 2 (0.0)                     | 1.000   |
| Central nervous system infection | -                   | 5 (0.0)                     | 1.000   |
| Peripheral nervous system disordersd| -                   | 15 (0.1)                    | 1.000   |
| **Respiratory and constitutional symptoms, n (%)** |                       |                             |         |
| Fever                   | 107 (43.8)            | 3820 (35.9)                 | 0.011   |
| Cough                   | 128 (52.5)            | 4263 (40.3)                 | <0.001  |
| Dyspnea                 | 98 (40.2)             | 2605 (24.5)                 | <0.001  |
| Rhinorrhea              | 9 (2.7)               | 598 (5.6)                   | 0.190   |
| Sputum production       | 28 (11.5)             | 609 (5.7)                   | <0.001  |
| Sore throat             | 15 (6.2)              | 736 (6.9)                   | 0.638   |
| Diarrhea                | 19 (7.8)              | 578 (5.4)                   | 0.111   |
| Fatigue                 | 16 (6.6)              | 697 (6.6)                   | 0.998   |
| Others                  | 53 (21.7)             | 1621 (15.2)                 | 0.006   |
| **New onset neurological symptoms, n (%)** |                       |                             |         |
| Headache                | 10 (4.1)              | 597 (5.6)                   | 0.308   |
| Nausea or vomiting      | 8 (3.3)               | 150 (1.4)                   | 0.026   |
| Seizure                 | 5 (2.0)               | 91 (0.9)                    | 0.064   |
| Altered mental statee   | 29 (11.5)             | 490 (4.6)                   | <0.001  |
| Olfactory or taste dysfunction | 14 (5.7)            | 649 (6.1)                   | 0.814   |
| Dysfunctions of other sensesf | 9 (3.7)             | 157 (1.5)                   | 0.012   |
| Bulbar symptomsg        | 3 (1.2)               | 119 (1.1)                   | 0.755   |
| Motor symptoms          | 13 (5.3)              | 233 (2.2)                   | 0.001   |
| Sensory symptoms        | 4 (1.6)               | 49 (0.5)                    | 0.031   |
| Myalgia                 | 5 (2.0)               | 251 (2.4)                   | 0.752   |
| Othersh                 | 33 (1.3)              | 450 (4.2)                   | 1.000   |
| **New-onset neurological disorders/complications, n (%)** |                       |                             | <0.001  |
| Encephalopathyi         | 35 (14.3)             | 609 (5.7)                   |         |
| Symptomatic seizure/status epilepticus | 7 (2.9)            | 118 (1.1)                   | 0.022   |
| Stroke/cerebrovascularj | 13 (5.3)              | 354 (3.3)                   | 0.087   |

(Continued)
cancer. Only altered mental status was shown to be more in those with cancer. The presence of new-onset neurologic manifestations could be explained by the COVID-19 infection itself, as reported in a meta-analysis showing that COVID 19 may manifest primarily or initially with neurologic manifestations (18). This neurologic involvement was also seen neuropathologically, where direct central nervous system involvement was documented (19). Although the direct relationship between COVID 19 and its effect on the nervous system is yet to be fully established, it has been postulated that there is the presence of severe hemorrhage and hypoxia, increased thrombotic events (as seen in infections like COVID 19), acute disseminated encephalomyelitis – like changes, encephalitis, and meningitis. Lastly, there have been reports of SARS-CoV-2 (the causative agent of COVID 19) reactivity in the brain (19). While COVID-19 patients present with abnormal electroencephalograms, these are not specific for COVID 19 alone and may be attributed to COVID-19 causing inflammation in the brain or other extracranial causes of encephalopathy (20).

A study done in Europe analyzed 1044 patients with active cancer diagnosed with COVID 19 and their outcomes, around 30.6% patients in the study died, while 92.5% of whom had a cause of death recorded as due to COVID-19. Furthermore, the all-cause case-fatality rate in patients with cancer who were infected with COVID-19 was significantly associated with sex and older age (21). A meta-analysis done in China included 15 studies from different countries around the world showed that the overall case fatality rate of COVID 19 patient with cancer was 22.4% (22). The relationship between cancer an COVID 19 was further established by another study which analyzed patients with cancer who were recently and had infection with COVID 19. It showed cancer patients who underwent recent chemotherapy and were associated with worse outcomes. This is explained by the possible immunosuppressive effects of chemotherapy (4).

The other effects of the pandemic on patients with cancer include tumor stage migration and higher early mortality which are both directly and indirectly caused. A study showed that there were more patients seen during the pandemic that presented to have inoperable or metastatic cancer (49.8% vs 39%). This meant poorer prognosis and that these patients most likely would only warrant palliative care (chemotherapy and/or radiotherapy) instead of being seen at an earlier stage or less extensive disease in which curative treatment (surgery, chemotherapy, and/or radiotherapy) maybe be offered (23). The 90-day mortality after the diagnosis of cancer was also higher during the pandemic at 10.5% vs 6.6%. The reason cited in the study was the higher rate of advanced disease at first referral/ diagnosis which was attributed to the indirect effect of the pandemic from the lockdowns and logistical limitations for patients to seek consult and have work-up done (23). Another study supported the findings of the study cited earlier wherein, as compared to the pre-pandemic times, the diagnosis of the six most common types of cancers were lesser (24). It does not mean that the actual incidence of cancer has decreased but most likely, the ability of patients to seek consult and the facilities to conduct

---

**TABLE 1**

| Treatment | n (%) |
|-----------|-------|
| **Glucocorticoids** | 2751 (25.9) |
| **Antivirals** | 1842 (17.3) |
| **Antibacterial** | 8793 (82.7) |
| **Others** | 3809 (35.9) |

| With cancer (n = 244) | Without cancer (n = 10,637) |
|-----------------------|-----------------------------|
| **Central nervous system infection** | 7 (0.1) | 1.000 |
| **Others** | 14 (0.1) | 1.000 |

| Treatment | n (%) |
|-----------|-------|
| **Glucocorticoids** | 93 (38.1) |
| **Antivirals** | 60 (24.6) |
| **Antibacterial** | 221 (90.6) |
| **Others** | 96 (39.3) |

---

[... rest of the text]
the work-up for the diagnosis of cancer have been hampered due to the logistic limitations caused by the pandemic.

The results of this study allowed us to understand the consequences of COVID-19 on adult patients with cancer. First, mortality rate of adult hospitalized cancer patients with COVID-19 was high, with estimates at around 32-33%. Second, cancer was also associated with longer hospital stays, respiratory failure, and needing ICU admission. Third, COVID-19 patients with cancer needed more interventions like steroids, antivirals, and antibiotics. These pieces of information may provide context and ideas for other investigators to write and conduct prospective studies and/or randomized clinical trials for this specific vulnerable subgroup.

The investigators have identified several limitations of this study. First, a detailed history on the cancer of the participants could have given us more insight on other relevant variables and their relationships; Since poorer functional status and those presently receiving cytotoxic chemotherapy had poorer outcomes compared to those who were deemed to have been cured of their cancer, with the latter having comparable outcomes to those with no cancer (25). Second, only the history of cancer was noted; with no data on the type of cancer, site, stage, and treatment history. The retrospective nature of the study was also subject to recall and selection bias. With the limitations identified, we recommend that a more detailed cancer history be taken with a prospective study design to corroborate our conclusions.

The findings in this study raise the need to further investigate patients with cancer, focusing on the type and stage of their cancer, as well as the status of their needs and treatment in relation to the pandemic. The data also stresses the importance of giving more support to vulnerable groups like patients with cancer during this time of the pandemic, in order to improve their outcomes. Furthermore, this study adds to the body of knowledge regarding COVID 19 and cancer. Physicians will be able to prognosticate this cohort of patients and government agencies in charge of the pandemic response will be able to

| TABLE 2 | Clinical outcomes of COVID-19 patients stratified according to having cancer or without. |

| Outcomes                        | With cancer (n = 244) | Without cancer (n = 10,637) | p-value |
|---------------------------------|-----------------------|-----------------------------|---------|
| **COVID-19 severity at nadir**  |                       |                             |         |
| Mild/moderate, n (%)            | 115 (47.9)            | 6575 (62.6%)                |         |
| Severe/critical, n (%)          | 125 (52.1)            | 3936 (37.4%)                |         |
| **In-hospital mortality, n (%)**|                       |                             |         |
| Time to in-hospital mortality in days, median (IQR) | 15 (9) | 15 (14) | 0.613 |
| **Respiratory failure, n (%)**  |                       |                             |         |
| Time to respiratory failure in days, median (IQR) | 76 (31.2) | 152 (14.4) | 0.001 |
| Duration of IMV in days, median (IQR) | 13 (10.5) | 13 (11.2) | 0.899 |
| IMV dependence ≤ 5 days, n (%) | 10 (4.1) | 208 (2) | 0.032 |
| IMV dependence > 5 days, n (%) | 234 (95.9) | 10,429 (98) | 0.001 |
| **Admitted to ICU, n (%)**      |                       |                             |         |
| Time to ICU admission in days, median (IQR) | 4.5 (3) | 5 (4) | 0.721 |
| Length of ICU stay in days, median (IQR) | 15 (10) | 15 (12) | 0.986 |
| ICU stay ≤ 7 days, n (%)        | 9 (11.5) | 263 (15.8) | 0.308 |
| ICU stay > 7 days, n (%)        | 69 (88.5) | 1399 (84.2) | 0.026 |
| **Length of hospital stay** in days, median (IQR) | 14 (10) | 13 (9) | 0.029 |
| Hospital stay ≤ 14 days, n (%) | 131 (53.7) | 6446 (60.6) | 0.029 |
| Hospital stay > 14 days, n (%) | 113 (46.3) | 4191 (39.4) | 0.001 |
| **Neurologic presentation or complication, n (%)** | 80 (32.8) | 2211 (20.8) | 0.006 |
| Neurologic outcomeb | 34 (72.3) | 1605 (86.4) |         |
| No recovery, n (%)             | 13 (27.7) | 253 (13.6) |         |

ICU, intensive care unit; IMV, invasive mechanical ventilation; IQR, interquartile range.

| TABLE 3 | Association of having a cancer with the different outcomes of interest. |

| Outcomes* | Crude OR | 95% CI | Adjusted OR* | 95% CI |
|-----------|----------|--------|--------------|--------|
| Severe/critical COVID-19 at nadir | 1.82 | 1.41, 2.35 | 1.75 | 1.32, 2.33 |
| Neurological presentation/complication | 1.86 | 1.42, 2.44 | 1.54 | 1.17, 2.03 |
| Full/partial neurological improvement | 0.41 | 0.21, 0.79 | 0.46 | 0.22, 0.93 |
| IMV dependence > 5 days | 0.47 | 0.24, 0.89 | 0.58 | 0.3, 1.13 |
| ICU stay > 7 days | 1.44 | 0.71, 2.92 | 1.39 | 0.68, 2.83 |
| Hospital stay > 14 days | 1.33 | 1.03, 1.71 | 1.22 | 0.94, 1.58 |

IMV, invasive mechanical ventilation; ICU, intensive care unit.

*Individual univariate multiple logistic regression analysis with independent variable malignancy adjusted for age group, sex, smoking history, hypertension, diabetes, chronic cardiac disease, chronic kidney disease, chronic respiratory disease, and chronic neurologic disease.
appropriately categorize patients with cancer as a priority for vaccinations and should also be given exceptions to logistic restrictions when seeking treatment.

**CONCLUSION**

A history of cancer conferred poorer clinical outcomes on adult, hospitalized patients with COVID-19 with increased mortality, respiratory failure, and need for ICU admission. Other demographic and clinical risk factors associated with cancer patients with COVID-19 were older age, female sex, multiple co-morbidities, and having more respiratory symptoms and neurologic manifestations.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**AUTHOR CONTRIBUTIONS**

AE: Conceptualization, data curation, formal analysis, interpretation of data, writing-original draft, writing-review, and editing. RL: Data curation, formal analysis, interpretation of data, writing-original draft, writing-review, and editing. MS: Conceptualization, data curation, formal analysis, interpretation of data, writing-review, and editing. EV: Data curation, formal analysis, interpretation of data, and editing. VA: Conceptualization, data curation, formal analysis, interpretation of data, writing-review, and editing. RJ: Conceptualization, data curation, formal analysis, interpretation of data, writing-original draft, writing-review, and editing. All authors contributed to the article and approved the submitted version.

**ACKNOWLEDGMENTS**

We would like to thank the members of the The Philippine CORONA Study Group for their contributions: Asian Hospital and Medical Center, Muntinlupa City (Corina Maria Socorro A. Macalintal, MD; Joanne B. Robles, MD), Baguio General Hospital...
REFERENCES

1. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta BioMed (2020) 91(1):157–60. doi: 10.23750/abm.v91i1.9397

2. Coronavirus (COVID-19) Vaccinations Statistics and Research – Our World in Data (2022). Available at: https://ourworldindata.org/covid-vaccinations?country=OWID_WRL (Accessed January 17, 2022).

3. Department of Health (Philippines) (2021). Available at: https://doh.gov.ph/2019-nCov (Accessed September 8, 2021).

4. Chavez-MacGregor M, Lei X, Zhao H, Sneath P, Giordano SH. Evaluation of COVID-19 Mortality and Adverse Outcomes in US Patients With or Without Cancer. JAMA Oncol (2022) 8(1):69–78. doi: 10.1001/jamaoncol.2021.5148

5. Bertuzzi AF, Ciccarelli M, Marrari A, Gennaro N, Dipasquale A, Giordano L, et al. Impact of Active Cancer on COVID-19 Survival: A Matched-Analysis on 557 Consecutive Patients at an Academic Hospital in Lombardy, Italy. Br J Cancer (2021) 125:358–65. doi: 10.1038/s41416-021-01396-9

6. Albigns I, Foulon S, Bayle A, Gachot B, Pommeret F, Willekens C, et al. Determinants of the Outcomes of Patients With Cancer Infected With SARS-CoV-2: Results From the Gustave Roussy Cohort. Nat Cancer (2020) 1:965–75. doi: 10.1038/s43018-020-00120-5

7. Garasino MC, Whisenant JG, Huang LC, Trama A, Torri V, Agostoni F, et al. Clinical Impact of COVID-19 on Patients With Cancer (CC19): A Cohort Study. Lancet (2020) 395(10241):1907–18. doi: 10.1016/S0140-6736(20)31187-9

8. Espiritu AI, Sy MC, Anlacan VM, Jamora RD. The Philippine COVID-19 Outcomes: A Retrospective Study Of Neurological Manifestations and Associated Symptoms (The Philippine CORONA Study). J Neural Trans (Vienna) (2021) 128(11):1687–703. doi: 10.1007/s00702-021-02400-5

9. Espiritu AI, Sy MC, Anlacan VM, Jamora RD. The Philippine CORONA Study Group Investigators. COVID-19 Outcomes of 10,881 Patients: Retrospective Study Of Neurological Symptoms and Associated Manifestations (Philippine CORONA Study). J Neural Trans (Vienna) (2021) 128(11):1687–703. doi: 10.1007/s00702-021-02400-5

10. Yang K, Sheng Y, Huang C, Jin Y, Xiong N, Jiang K, et al. Clinical Characteristics, Outcomes, and Risk Factors for Mortality in Patients With Cancer and COVID-19 in Hubei, China: A Multicentre, Retrospective, Cohort Study. Lancet Oncol (2020) 21(7):904–13. doi: 10.1016/S1470-2045(20)30310-7

11. Pinato DJ, Zambelli A, Aguilar-Company J, Bowler M, Sng C, Salazar R, et al. Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients With Cancer. Cancer Discov (2020) 10(10):1465–74. doi: 10.1158/2159-8290.CD-20-0773

12. Miyashita H, Mikami T, Chopra N, Yamada T, Chernyavsky S, Rizk D, et al. Do Patients With Cancer Have a Poorer Prognosis of COVID-19? An Experience in New York City. Ann Oncol (2020) 31(8):1088–9. doi: 10.1016/j.annonc.2020.04.006

and Medical Center, Baguio City (Paulo L. Cataniag, MD; Manolo Kristoffer C. Flores, MD, MBA), Cagayan Valley Medical Center, Tuguegarao City (Noreen Jhonna C. Tanguanco-Trinidad, MD), Capitol Medical Center, Quezon City (Dan Neftalie A. Juango, MD; Giuliano Renz G. Paas, MD), Cardinal Santos Medical Center, San Juan City (Audrey Marie U. Chua, MD, Valmari Estrada, MD; Philip Rico P. Mejia, MD; Therese Franz B. Reyes, MD), Chong Hua Hospital, Cebu City (Maria Teresa A. Cañete, MD; Ferdinand Renfred A. Zapata, MD), De La Salle University Medical and Health Sciences Institute, Dasmariñas City, Cavite (Francisco Eugenio B. Castillo, MD; Romulo U. Esagunde, MD; Jean B. Gantioque, MD), Dr. Jose N. Rodriguez Memorial Hospital, Caloocan City (Maritoni C. Abbabiao, MD; Tamura, MD; Rizza J. Umali, MD), New Era General Hospital, Davao City (Evram V. Corral, MD), Lung Center of the Philippines, Quezon City (Romulus Emmanuel H. Cruz, MD; Alenlee Lee, MD; Nadia O. Manlegro, MD; Dave Mar Palere, MD) St. Luke’s Medical Center, Bonifacio Global City, Taguig City (Lina C. Lacamana, MD; Diana-Lynn S. Que, MD; Jeryl Ritzi T. Yu, MD), St. Luke’s Medical Center, Quezon City (Ma. Socorro C. Martinez, MD; Alexandra E. Matic, MD; John Angelo S. Perez, MD), The Medical City, Pasig City (Glen Anthony A. Constantino, MD; Aldanica R. Olano, MD; Liz Edenberg P. Quiles, MD; Artemio A. Roxas, Jr, MD; Jo Ann R. Soliven, MD; Michael Dorothy Frances Montojo-Tamayo, MD), University of Santo Tomas Hospital, Manila (Ma. Lourdes P. Corrales-Joson, MD; Jojo R. Evangelista, MD), University of the East Ramon Magsaysay Memorial Medical Center, Inc., Quezon City (Ma. Clarissa B. Nuñez, MD; Marietta C. Olivar, MD; Dominique Q. Perez, MD), Veterans Memorial Medical Center, Quezon City (Mark Deneb O. Armeña, MD; Robert A. Barja, MD), Vicente Sotto Memorial Medical Center, Cebu City (Joshua Emmanuel E. Abejero, MD; Maritzie R. Erilbal, MD), Western Visayas Medical Center, Iloilo City (Ryndell G. Alava, MD), Zamboanga City Medical Center, Zamboanga City (Muktader A. Kelbi, MD; Nasheera W. Radja, MD; Mohammad Elshad S. Sali, MD).
13. Mehta V, God S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, et al. Case Fatality Rate of Cancer Patients With COVID-19 in a New York Hospital System. Cancer Discov (2020) 10(7):935–41. doi: 10.1158/2159-8290.CD-20-0516

14. Mondia MW, Espiritu AI, Batara JM, Jamora RD. Neuro-Oncology in the Philippines: A Scoping Review on the State of Medical Practice, Deterrents to Care and Therapeutic Gaps. Ecancernmedicalscience (2021) 15:1238. doi: 10.3332/ecancer.2021.1238

15. Dayrit MM, Lagrada LP, Picazo OF, Pons M, Villaverde M. The Philippines Health System Review. In: Patchharrananurul W, Tangcharoensathien V, editors. Health Systems in Transition. Geneva: WHO Press (2018). p. 1–316.

16. Brugel M, Carlier C, Essner C, Debreuve-Theresette A, Beck MF, Merrouche Y, et al. Dramatic Changes in Oncology Care Pathways During the COVID-19 Pandemic: The French ONCOCARE-COV Study. Oncologist (2021) 26(2):e338–41. doi: 10.1002/onco.13578

17. Al-Shamsi HO, Alhazzani W, Alburaiji A, Coomes EA, Chemaly RF, Almuhanna M, et al. A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group. Oncologist (2020) 25(6):e936–45. doi: 10.1634/theoncologist.2020-0213

18. Collantes ME, Espiritu AI, Sy MC, Alnacan VM, Jamora RD. Neurological Manifestations in COVID-19 Infection: A Systematic Review and Meta-Analysis. Can J Neurol Sci (2021) 48(1):66–76. doi: 10.1017/cjn.2020.146

19. Pajo AT, Espiritu AI, Apor AD, Jamora RD. Neuropathologic Findings of Patients With COVID-19: A Systematic Review. Neurol Sci (2021) 42(4):1255–66. doi: 10.1007/s10072-021-05068-7

20. Roberto KT, Espiritu AI, Fernandez ML, Gutierrez JC. Electroencephalographic Finding in COVID-19 Patients: A Systematic Review. Seizure (2020) 82:17–22. doi: 10.1016/j.seizure.2020.09.007

21. Lee LY, Cazier JP, Starkey T, Briggs SE, Arnold R, Bisht V, et al. COVID-19 Prevalence and Mortality in Patients With Cancer and the Effect of Primary Tumour Subtype and Patient Demographics: A Prospective Cohort Study. Lancet Oncol (2020) 21(10):1509–16. doi: 10.1016/S1470-2045(20)30442-3

22. Zhang H, Han H, He T, Labbe KE, Hernandez AV, Chen H, et al. Clinical Characteristics and Outcomes of COVID-19–Infected Cancer Patients: A Systematic Review and Meta-Analysis. J Natl Cancer Inst (2021) 113(4):371–80. doi: 10.1093/jnci/djaa168

23. Guven DC, Sahin TK, Yildirim HC, Cesmeci E, Incesu FGG, Tahliloglu Y, et al. Newly Diagnosed Cancer and the COVID-19 Pandemic: Tumour Stage Migration and Higher Early Mortality. BMJ Support Palliat Care (2021): bmjspcare-2021-003301. doi: 10.1136/bmjspcare-2021-003301

24. Kaufman HW, Chen Z, Niles J, Pesko Y. Changes in the Number of US Patients With Newly Identified Cancer Before and During the Coronavirus Disease 2019 (COVID-19) Pandemic. JAMA Netw Open (2020) 3(8): e2017267. doi: 10.1001/jamanetworkopen.2020.17267.s

25. Ospina AV, Bruges R, Mantilla W, Triana I, Ramos P, Aruachan S, et al. Impact of COVID-19 Infection on Patients With Cancer: Experience in a Latin American Country: The ACHOCC-19 Study. Oncologist (2021) 26(10):e1761–73. doi: 10.1002/onco.13861

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Espiritu, Larrazabal, Sy, Villanueva, Alnacan and Jamora. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.